ArticleOncology letters2025
Application of serum anti-ENO1 and anti-SSNA1 antibody biomarkers in predicting the prognosis of gastric cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enolase 1: A paradigm of metabolic enzyme moonlighting in tumorigenesis (Review).International journal of oncology · 2026Review
- Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.Annals of gastroenterological surgery · 2026Review
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the high malignancy of advanced gastric cancer, the identification of biomarkers for the diagnosis and prognosis prediction of advanced gastric cancer is of importance. The present study conducted the serological identification of antigens by recombinant cDNA expression cloning and determined enolase 1 (ENO1) and Sjögren syndrome nuclear autoantigen 1 (SSNA1) as tumor antigens recognized by serum immunoglobulin G (IgG) antibodies in patients with gastric cancer. The clinicopathological significance of preoperative autoantibodies were assessed, namely serum anti-ENO1 antibodies (s-ENO1-Abs) and serum anti-SSNA1 antibodies (s-SSNA-Abs), in the sera of 166 patients with gastric cancer who underwent radical surgery and 96 healthy donors. The s-ENO1-Ab and s-SSNA-Ab titer levels were significantly increased in patients with gastric cancer compared with that in healthy donors (P<0.01). Areas under the receiver operating characteristic curves of s-ENO1-Ab and s-SSNA1-Ab were 0.656 and 0.607, respectively. None of the clinicopathological factors, such as sex, age, histological type, tumor size, tumor depth, nodal status, cytology, peritoneal dissemination and stage demonstrated association with the s-ENO1-Ab or s-SSNA1-Ab titer levels. High s-ENO1-Ab and s-SSNA1-Ab titer levels were associated with improved overall survival, but the differences were not statistically significant. According to the Human Protein Atlas dataset, high mRNA expression levels of ENO1 and SSNA1 showed a trend towards shorter overall survival, while low expression levels showed a trend towards longer overall survival (ENO1: P=0.07, SSNA1: P<0.05). Combination analysis indicated that the s-ENO1-Ab-positive (+)/carcinoembryonic antigen (CEA)-negative (-) group demonstrated a significantly improved prognosis compared with that of the s-ENO1-Ab(-)/CEA(+) group (P<0.01), while a comparison of the s-SSNA1-Ab(+)/CEA(-) group with the s-SSNA1-Ab(-)/CEA(+) group also demonstrated a significant improvement in prognosis (P<0.01). Thus, s-ENO1-Abs and s-SSNA-Abs may be useful biomarkers for predicting gastric cancer prognosis, providing future research directions for novel approaches to target and treat gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.